But, for BNTX, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

So it is worth checking the past earnings trajectory of BioNTech, (below). Of course, keep in mind that there are other factors to consider, too. NasdaqGS:BNTX Earnings and Revenue Growth January ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

According to data from Benzinga Pro, BNTX has a 52-week high of $131.49 and a 52-week low of $76.53.

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...